Department of Haematology, 10173University Medical Centre Groningen, University of Groningen, Groningen, the Netherlands.
Department of Internal Medicine, Division of Infectious Diseases, 10173University Medical Centre Groningen, University of Groningen, Groningen, the Netherlands.
Clin Appl Thromb Hemost. 2023 Jan-Dec;29:10760296231165492. doi: 10.1177/10760296231165492.
Trends of coagulation parameters during long-term treatment with combination antiretroviral therapy (cART) are unclear. We followed 40 male subjects living with human immunodeficiency virus (HIV). Plasma levels of procoagulant parameters, factor VIII, von Willebrand factor and D-dimer, and anticoagulant parameter Protein S (PS), were measured before start and 3 months, 1 year, and 9 years after. Analyses were adjusted for cardiovascular risk factors (age, smoking, and hypertension) at baseline. At baseline, procoagulant parameters were markedly elevated and PS was in the lower range of normal. CD4/CD8-ratio improved during the complete follow-up period. In the first year, procoagulant parameters were decreasing, but at year 9 an increase was observed. After correction for cardiovascular risk factors, this increase was no longer present. PS remained stable during the first year and slightly increased from one to 9 years. This study indicates that decreasing immune activation by cART reverses the procoagulant state in HIV partially during the first year. These parameters increase in the long term despite an on-going decrease in immune activation. This increase might be related to established cardiovascular risk factors.
长期接受联合抗逆转录病毒疗法(cART)治疗期间凝血参数的变化趋势尚不清楚。我们随访了 40 名男性艾滋病毒(HIV)感染者。在开始治疗前和治疗后 3 个月、1 年和 9 年,分别测量了促凝参数、VIII 因子、血管性血友病因子和 D-二聚体以及抗凝参数蛋白 S(PS)的血浆水平。分析时对基线时的心血管危险因素(年龄、吸烟和高血压)进行了校正。在基线时,促凝参数明显升高,PS 在正常范围的低值。CD4/CD8 比值在整个随访期间得到改善。在第一年,促凝参数下降,但在第 9 年观察到增加。在对心血管危险因素进行校正后,这种增加不再存在。PS 在第一年保持稳定,从一年到九年略有增加。本研究表明,cART 通过降低免疫激活,在第一年部分逆转了 HIV 的促凝状态。尽管免疫激活持续下降,但这些参数在长期内仍会增加。这种增加可能与已确立的心血管危险因素有关。